Pharmacokinetic profile of Arthrospira maxima-derived phycocyanobilin. Development and application of a novel bioanalytical method
摘要
C-Phycocyanin (CPC) is noted for its antioxidant, anti-inflammatory, and anticancer properties. However, it is a prodrug catabolized to phycocyanobilin (PCB) when it is administered orally into the digestive tract to induce its pharmacological effect. Yet, the PCB pharmacokinetic and pharmacodynamic profile remains unknown. Following the United States Food and Drug Administration and Mexican guidelines, this study developed and validated a sensitive ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) bioanalytical method for quantifying PCB in plasma. Key findings included a detection range of 5–80 ng mL−1 PCB through acetonitrile protein precipitation. Finally, the validated method was successfully applied on the pharmacokinetics of PCB after an oral administration (50 mg kg−1) in mice; including time to reach maximum concentration (0.04 ± 0.01 h), maximum concentration (40.19 ± 6.35 ng mL−1), half-life (3.36 ± 0.83 h), first-order rate constant of the drugs transfer from the central compartment to the peripheral compartment (K12 = 0.12 ± 0.04 h−1), first-order elimination rate constant (K10 = 0.12 ± 9.22 h−1), apparent volume of distribution (5708.51 ± 1965.76 L kg−1), apparent clearance (1168.46 ± 201.63 L h−1 kg−1) and area under the plasma concentration–time curve from time zero to the last time (27.27 ± 2.78 h). In conclusion, a sensitive, accurate, and precise LC–MS method was successfully applied to determine PCB pharmacokinetic parameters after a single dose administration.